Active Clinical Trials

Active Clinical Trials at Huron Gastro are listed below. If you have any questions about our current research, please contact our research department at (735) 418-7736.

Active Clinical Trials

 

  • A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) (GS-US-454-6075)
     

  • A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects with Nonalcoholic Steatohepatitis (Nash) (Harmony, AK-US-001-0102) 

  • In Active Ulcerative Colitis- A Randomized Controlled Trial for Determination of the Optimal Treatment Target (Treatment algorithms will feature the use of Vedolizumab) (VERDICT, RP-1706)

  • A Phase 2, randomized, double-blind, placebo-controlled, multi-center study to evaluate GB004 in adult subjects with mild-to-moderate active ulcerative colitis (GB004-2101)

  • A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease (Apollo PR200-103)

  • A Study to Assess the Genotype of Subjects with Diagnosis of Ulcerative Colitis or Crohn’s Disease (PRELUDE PR100-105)

  • An Open-Label Extension and Saftey Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies (GA28951, Cottonwood)
     

  • A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease (GALAXI, CNTO1959CRD3001) 

  • A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in subjects with Ulcerative Colitis (AbbVie M14-533)
     
  • A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcohlic Steatohepatitis (REGENERATE, 747-303) 
     
  • A Phase 4 Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (AbbVie LEGACY)